Inclusion Criteria:

- Age >=18 years.

- Histological or cytological documentation of non hematologic, malignant solid tumour.

- Have failed at least one previous therapeutic regimen.

- Measurable disease according to RECIST 1.1.

- Life expectancy >= 12 weeks

- ECOG Performance Status of 0 or 1

- Written, signed and dated informed consent

- Able and willing to meet all protocol-required treatments, investigations and visits.

- Have adequate organ function

Exclusion Criteria:

- Clinically significant non-malignant disease.

- Active CNS metastases.

- Subjects with uncontrolled diabetes.

- History of clinically significant adverse drug reaction to heparin or other
anti-coagulant agents

- History of immune-mediated thrombocytopaenia or other platelet abnormalities or other
hereditary or acquired coagulopathies.

- Concomitant use of aspirin (> 150 mg/day), NSAIDs (except COX-2 selective
inhibitors), vitamin K antagonists (other than low-dose prophylactic use), heparin
within two weeks prior to randomisation, or other anti-platelet drugs.

- History of severe allergic, anaphylactic or other significant adverse reaction to
radiographic contrast media

- Known seropositivity to the human immunodeficiency virus (HIV)

- Women who are pregnant or breast-feeding.

- Women of child-bearing potential and male subjects who are partners of women of
childbearing potential who are unable or unwilling to practice a highly effective
means of contraception.

- Active substance abuse

- Subjects who have received an investigational agent within 28 days prior to Cycle 1
Day 1.